Agios Pharmaceuticals AGIO Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.
The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Agios Pharmaceuticals's debt securities, available-for-sale, accumulated gross unrealized loss, before tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Agios Pharmaceuticals's debt securities, available-for-sale, accumulated gross unrealized loss, before tax?
- Agios Pharmaceuticals (AGIO) reported debt securities, available-for-sale, accumulated gross unrealized loss, before tax of $1.04M in Q1 2026.
- How has Agios Pharmaceuticals's debt securities, available-for-sale, accumulated gross unrealized loss, before tax changed year-over-year?
- Agios Pharmaceuticals's debt securities, available-for-sale, accumulated gross unrealized loss, before tax increased by 11.1% year-over-year, from $933K to $1.04M.
- What is the long-term trend for Agios Pharmaceuticals's debt securities, available-for-sale, accumulated gross unrealized loss, before tax?
- Over 5 years (2020 to 2025), Agios Pharmaceuticals's debt securities, available-for-sale, accumulated gross unrealized loss, before tax has grown at a -22.3% compound annual growth rate (CAGR), from $216K to $61K.